Search Result

Results for "

MAPK+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (5) Autophagy (24) Bcl-2 Family (2) c-Met/HGFR (1) Casein Kinase (3) Caspase (2) CDK (1) EGFR (1) Endogenous Metabolite (2) ERK (3) Herbicide (1) HSP (2) Interleukin Related (3) Isotope-Labeled Compounds (1) JNK (2) Keap1-Nrf2 (1) Microtubule/Tubulin (1) Mitophagy (4) MMP (1) NF-κB (3) Organoid (4) p38 MAPK (71) PARP (1) PI3K (1) PKC (2) Prostaglandin Receptor (1) Raf (3) Reactive Oxygen Species (ROS) (4) Reference Standards (9) Scavenger Receptor Class B type I (SR-BI） (2) Src (2) TNF Receptor (6) Wnt (2)
By Research Areas:	Cancer (31) Cardiovascular Disease (6) Endocrinology (2) Infection (1) Inflammation/Immunology (52) Metabolic Disease (3) Neurological Disease (3)

By Targets:

Akt (1)

Apoptosis (5)

Autophagy (24)

Bcl-2 Family (2)

c-Met/HGFR (1)

Casein Kinase (3)

Caspase (2)

CDK (1)

EGFR (1)

Endogenous Metabolite (2)

ERK (3)

Herbicide (1)

HSP (2)

Interleukin Related (3)

Isotope-Labeled Compounds (1)

JNK (2)

Keap1-Nrf2 (1)

Microtubule/Tubulin (1)

Mitophagy (4)

MMP (1)

NF-κB (3)

Organoid (4)

p38 MAPK (71)

PARP (1)

PI3K (1)

PKC (2)

Prostaglandin Receptor (1)

Raf (3)

Reactive Oxygen Species (ROS) (4)

Reference Standards (9)

Scavenger Receptor Class B type I (SR-BI） (2)

Src (2)

TNF Receptor (6)

Wnt (2)

By Research Areas:

Cancer (31)

Cardiovascular Disease (6)

Endocrinology (2)

Infection (1)

Inflammation/Immunology (52)

Metabolic Disease (3)

Neurological Disease (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10256

Adezmapimod Maximum Cited Publications 601 Publications Verification SB 203580; RWJ 64809	Organoid p38 MAPK Autophagy Mitophagy HSP	Inflammation/Immunology Cancer
Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .

HY-50846

SCH772984 180+ Cited Publications	ERK	Cancer
SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC₅₀s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-na?ve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations .

HY-10320

Doramapimod 50+ Cited Publications BIRB 796	p38 MAPK Raf Autophagy	Inflammation/Immunology Cancer
Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC₅₀ for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (K_d=0.1 nM). Doramapimod also inhibits B-Raf with an IC₅₀ of 83 nM .

HY-10402

Losmapimod 10+ Cited Publications GSK-AHAB; GW856553X; SB856553	p38 MAPK Autophagy	Inflammation/Immunology Cancer
Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pK_is of 8.1 and 7.6 for p38α and p38β, respectively .

HY-10256A

Adezmapimod hydrochloride Maximum Cited Publications 601 Publications Verification SB 203580 hydrochloride; RWJ 64809 hydrochloride	Organoid p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride does not disrupt JNK activity and is an autophagy and mitophagy activator .

HY-10456

TAK-715 10+ Cited Publications	p38 MAPK Casein Kinase Wnt	Inflammation/Immunology
TAK-715 is an orally active and potent p38 MAPK inhibitor with IC₅₀s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model .

HY-19900

ITX5061 3 Publications Verification	p38 MAPK Scavenger Receptor Class B type I (SR-BI）	Inflammation/Immunology
ITX5061 is an orally active type II non-competitive p38 MAPK inhibitor. ITX5061 increases HDL-C levels by inhibiting SR-BI activity. ITX5061 also moderately elevates ApoA-I levels. ITX5061 reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 can be used in the research of atherosclerosis .

HY-100115

TA-02 2 Publications Verification	p38 MAPK Autophagy	Cardiovascular Disease Inflammation/Immunology Cancer
TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC₅₀ of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295) .

HY-11068

SB 239063 30+ Cited Publications	p38 MAPK Autophagy	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC₅₀ of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD. SB 239063 can penetrate the blood brain barrier (BBB) .

HY-13241A

Ralimetinib 10+ Cited Publications LY2228820	p38 MAPK Autophagy	Cancer
Ralimetinib is an ATP-competitive p38α and p38β MAPK inhibitor with an IC₅₀ of 5.3 nmol/L against human p38α and an IC₅₀ of 3.2 nmol/L against human p38β. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma .

HY-10404

Dilmapimod 1 Publications Verification SB-681323; GW 681323	p38 MAPK Autophagy	Inflammation/Immunology Cancer
Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.

HY-100114

TA-01	Casein Kinase p38 MAPK Autophagy	Cardiovascular Disease
TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC₅₀s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively. TA-01 acts as a cardiogenic inhibitor.

HY-12511

SKF-86002 3 Publications Verification	p38 MAPK	Inflammation/Immunology
SKF-86002 is an orally active p38 MAPK inhibitor, with anti-inflammatory, anti-arthritic and analgesic activities. SKF-86002 inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production (IC₅₀ = 1 μM). SKF-86002 inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid .

HY-10405

Pamapimod 1 Publications Verification Ro4402257; R1503	p38 MAPK Autophagy	Inflammation/Immunology
Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC₅₀s of 14 nM and 480 nM and K_is of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .

HY-B2162D

Chondroitin sulfate (from chicken) Chondroitin polysulfate (from chicken)	ERK p38 MAPK Interleukin Related TNF Receptor Prostaglandin Receptor MMP Endogenous Metabolite	Inflammation/Immunology
Chondroitin sulfate (from chicken) (Chondroitin polysulfate (from chicken)) is an orally active, sulfated linear polysaccharide extracted from chickens, which belongs to glycosaminoglycans. Chondroitin sulfate (from chicken) reduces the phosphorylation levels of ERK1/2 and *p38MAPK*, inhibits the expression of inflammatory cytokines and MMP, and downregulates the levels of IL-1β, IL-6, TNF-α and PGE₂. Chondroitin sulfate (from chicken) improves motor function, protects cartilage tissue, reverses chondrocyte aggregation, and regulates the structure of intestinal flora. Chondroitin sulfate (from chicken) can be used in research related to osteoarthritis .

HY-112401

*p38 MAP Kinase Inhibitor* IV**	p38 MAPK	Inflammation/Immunology
p38 MAP Kinase Inhibitor IV is a highly specific ATP-competitive p38α MAPK inhibitor with IC₅₀s of 0.13 and 0.55 μM for p38α and p38β MAPK, respectively .

HY-112389

*p38 MAP Kinase Inhibitor* III** 2 Publications Verification	p38 MAPK	Inflammation/Immunology
p38 MAP Kinase Inhibitor III (compound 7h) is a p38 MAPK inhibitor with an ₅₀ of 0.9 μM. p38 MAP Kinase Inhibitor III also inhibits IL-1β and TNF-α release with ₅₀ values of 0.37 μM and 0.044 μM, respectively .

HY-135674

SR-318 1 Publications Verification	p38 MAPK TNF Receptor	Inflammation/Immunology Cancer
SR-318, a chemical probe, is a potent and highly selective p38 MAPK inhibitor with IC₅₀s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the TNF-α release in whole blood with an IC₅₀ of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity .

HY-18862

PF-03715455	p38 MAPK	Inflammation/Immunology
PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC₅₀ values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC₅₀=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) .

HY-14305A

BMS-582949 hydrochloride 2 Publications Verification	p38 MAPK Autophagy	Inflammation/Immunology
BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC₅₀ of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease .

HY-15505

RWJ-67657 JNJ 3026582	p38 MAPK	Cardiovascular Disease Inflammation/Immunology Cancer
RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC₅₀s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity .

HY-131335

*p38α inhibitor* 2**	p38 MAPK	Inflammation/Immunology
p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC₅₀ of 9.6. p38α inhibitor 2 inhibits the hERG ion channel (IC₅₀=27 μM) and shows a promising selectivity profile when tested in a panel of 51 other protein kinases (<30% inhibition at 10 μM concentration) and a panel of 141 other biological targets .

HY-112291

SB 220025	p38 MAPK Src PKC	Inflammation/Immunology
SB 220025 is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor (IC₅₀ = 60 nM). SB 220025 also inhibits p56 ^Lck and PKC with IC₅₀ values of 3.5 and 2.89 µM, respectively. SB 220025 inhibits the expression of IL-8 gene in response to globular adiponectin (gAd), reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 effectively prevents the progression of arthritis in a chronic inflammatory disease model and can be used in the study of inflammation .

HY-112466

*p38 MAPK-IN-4*	p38 MAPK	Inflammation/Immunology
p38 MAPK-IN-4 (compound 6) is a p38 MAPK inhibitor with an IC₅₀ of 35 nM .

HY-170879

JD123	p38 MAPK JNK	Cancer
JD123 inhibits JNK1 activity and the expression of cJun (1-135). JD123 is a ATP-competitive p38-γ MAPK inhibitor, but not effect to ERK1, ERK2, or p38-α, p38-β or p38-δ. .

HY-108645

AL 8697	p38 MAPK Autophagy	Inflammation/Immunology
AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC₅₀ of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC₅₀=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity .

HY-155736

MAPK-IN-2	p38 MAPK EGFR Raf CDK c-Met/HGFR	Cancer
MAPK-IN-2 (compound 3h) is a potent MAPK inhibitor with antineoplastic activity. MAPK-IN-2 inhibits cancer cell proliferation among serval cancer cell lines, and suppresses MAPK pathway with potant efficacy (EGFR ^WT IC₅₀=281 nM, c-MET IC₅₀=205 nM, B-RAF ^WT IC₅₀=112 nM, and CDK4/6 IC₅₀=95 and 184 nM, respectively). MAPK-IN-2 even shows a remarkable potency against mutated EGFR and B-RAF (EGFR ^T790M IC₅₀=69 nM and B-RAF ^V600E IC₅₀=83 nM) .

HY-10256R

Adezmapimod (Standard) SB 203580 (Standard); RWJ 64809 (Standard)	Organoid Reference Standards p38 MAPK Autophagy Mitophagy HSP	Inflammation/Immunology Cancer
Adezmapimod (Standard) is the analytical standard of Adezmapimod. This product is intended for research and analytical applications. Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .

HY-110103

ML3403	p38 MAPK	Inflammation/Immunology
ML3403 is a potent p38 MAPK inhibitor with an IC₅₀ of 0.38 μM .

HY-18759

BMS-751324	p38 MAPK TNF Receptor	Inflammation/Immunology
BMS-751324 is a p38α MAPK inhibitor. BMS-751324 equips a precursor of carbamyl-methyl linkage, containing esters and phosphate functional groups derived from hydroxyphenylacetic acid (HPA). BMS-751324 effectively inhibits foot swelling and LPS-induced TNFα production in an arthritic rat model .

HY-168482

*NF-κB/MAPK-IN-2*	NF-κB p38 MAPK	Cancer
NF-κB/MAPK-IN-2 (compound 14) is a potent NF-κB and *MAPK* Inhibitor. NF-κB/MAPK-IN-2 decreases the protein expression of p-p65, p-IκB, p-p38, p-JNK, and p-ERK. NF-κB/MAPK-IN-2 reduces the LPS-induced release of TNF-α and IL-6. NF-κB/MAPK-IN-2 inhibits nuclear translocation of p65 and c-Fos. NF-κB/MAPK-IN-2 has the potential for the research of sepsis .

HY-161462

*ERK2/p38α MAPK-IN-1*	ERK p38 MAPK	Cancer
ERK2/p38α MAPK-IN-1 (Compound 1, In silico Hit-2) is a potent and selective ERK2 and p38α MAPK inhibitor, with an IC₅₀ of 82 μM for ERK2. ERK2/p38α MAPK-IN-1 binds to the allosteric site of ERK2 and p38α MAPK in distinct manners. ERK2/p38α MAPK-IN-1 can be used for the research of type 2 diabetes .

HY-10256AR

Adezmapimod hydrochloride (Standard) SB 203580 hydrochloride (Standard); RWJ 64809 hydrochloride (Standard)	Organoid Reference Standards p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (hydrochloride) (Standard) is the analytical standard of Adezmapimod (hydrochloride). This product is intended for research and analytical applications. Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride does not disrupt JNK activity and is an autophagy and mitophagy activator .

HY-108644

SB 706504	p38 MAPK	Inflammation/Immunology
SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides (HY-D1056)-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD) .

HY-18754A

FR 167653 FR 167653 sulfate	p38 MAPK Autophagy	Endocrinology
FR 167653 (FR 167653 sulfate), an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 (FR 167653 sulfate) is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo .

HY-175175

MAPK-IN-5	p38 MAPK Bcl-2 Family Caspase Reactive Oxygen Species (ROS) PARP Apoptosis	Cancer
MAPK-IN-5 is a potent *MAPK* inhibitor with an IC₅₀ of 1.35 μM against HeLa cells. MAPK-IN-5 inhibits HeLa cell proliferation by inducing ROS-mediated DNA damage and mitochondrial apoptosis via the MAPK pathway. MAPK-IN-5 significantly inhibits colony formation, reduces the number of live cells, suppresses cell migration, and causes cell cycle arrest in the G2/M phase in HeLa cells. MAPK-IN-5 can be used for the study of cervical cancer .

HY-10404A

Dilmapimod tosylate SB-681323 tosylate; GW 681323 tosylate	p38 MAPK Autophagy	Inflammation/Immunology Cancer
Dilmapimod tosylate is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.

HY-49073

*p38 MAP Kinase Inhibitor* Ⅵ**	p38 MAPK	Cancer
p38 MAP Kinase Inhibitor VI (compound c32) is a p38 MAPK inhibitor with an inhibition rate of 24% .

HY-117152

L-threo-Sphingosine L-threo-Sphingosine C-18	p38 MAPK Apoptosis	Cancer
L-threo-Sphingosine is a potent *MAPK* inhibitor. L-threo-Sphingosine induces apoptosis and clear DNA fragmentation. L-threo-Sphingosine shows anticancer effect .

HY-169685

*p38 MAPK-IN-6*	p38 MAPK	Inflammation/Immunology
p38 MAPK-IN-6 (compound c47) is a p38 MAPK inhibitor. p38 MAPK-IN-6 shows 14% inhibition at 10 μM .

HY-144697

*p38 MAPK-IN-3*	p38 MAPK Apoptosis Reactive Oxygen Species (ROS)	Cancer
p38 MAPK-IN-3 (Compound 2c) is a p38α MAPK inhibitor. p38 MAPK-IN-3 has antitumor activities and induces apoptosis and ROS .

HY-10404R

Dilmapimod (Standard) SB-681323 (Standard); GW 681323 (Standard)	Reference Standards p38 MAPK Autophagy	Inflammation/Immunology Cancer
Dilmapimod (Standard) is the analytical standard of Dilmapimod. This product is intended for research and analytical applications. Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.

HY-10403A

(aS)-PH-797804	p38 MAPK	Inflammation/Immunology
(aS)-PH-797804 is a selective p38 MAPK inhibitor with IC₅₀ values for p38 α /β of 26 nM and 102 nM, respectively. (aS)-PH-797804 has anti-inflammatory activity .

HY-163114

2-Stearoxyphenethyl phosphocholin	p38 MAPK	Metabolic Disease
2-Stearoxyphenethyl phosphocholin (compound 1a) is a p38 MAPK inhibitor with anticancer activity. 2-Stearoxyphenethyl phosphocholin may bind to the p38 MAPK lipid-binding pocket and has broad-spectrum anti-tumor and lipid-modulating activities .

HY-163115

2-Oleoxyphenethyl phosphocholin	p38 MAPK	Cancer
2-Oleoxyphenethyl phosphocholin (compound 1b) is a p38 MAPK inhibitor with anticancer activity. 2-Oleoxyphenethyl phosphocholin may bind to the p38 MAPK lipid-binding pocket and has broad-spectrum anti-tumor and lipid-modulating activities .

HY-175431

*p38 MAPK-IN-8*	p38 MAPK	Inflammation/Immunology Cancer
p38 MAPK-IN-8 (Compound 8) is an orally active, potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor. p38 MAPK-IN-8 is promising for research of inflammatory responses, autoimmune diseases, and cancer .

HY-10402R

Losmapimod (Standard) GSK-AHAB (Standard); GW856553X (Standard); SB856553 (Standard)	Reference Standards p38 MAPK Autophagy	Inflammation/Immunology Cancer
Losmapimod (Standard) is the analytical standard of Losmapimod. This product is intended for research and analytical applications. Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively .

HY-146032

*p38-α MAPK-IN-4*	p38 MAPK	Neurological Disease Inflammation/Immunology
p38-α MAPK-IN-4 (Compound 69) is a selective p38α MAPK inhibitor with an IC₅₀ of 1.5 µM. p38-α MAPK-IN-4 rapidly and strongly prevents the development of mechanical allodynia (MA) in vivo .

HY-162364

*p38-α MAPK-IN-7*	p38 MAPK	Neurological Disease
p38-α MAPK-IN-7 (compound 4) is a *p38α-MAPK* inhibitor with an IC₅₀ value of 98.7 nM. p38-α MAPK-IN-7 protects neuronal cells from dexamethasone-induced ROS production .

HY-108641

SKF-86002 dihydrochloride	p38 MAPK	Inflammation/Immunology
SKF-86002 dihydrochloride is an orally active p38 MAPK inhibitor, with anti-inflammatory, anti-arthritic and analgesic activities. SKF-86002 dihydrochloride inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production (IC₅₀ = 1 μM). SKF-86002 dihydrochloride inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid .

Cat. No.	Product Name	Type

HY-B2162D

Chondroitin sulfate (from chicken)

Chondroitin polysulfate (from chicken)

Biochemical Assay Reagents

Chondroitin sulfate (from chicken) (Chondroitin polysulfate (from chicken)) is an orally active, sulfated linear polysaccharide extracted from chickens, which belongs to glycosaminoglycans. Chondroitin sulfate (from chicken) reduces the phosphorylation levels of ERK1/2 and p38MAPK, inhibits the expression of inflammatory cytokines and MMP, and downregulates the levels of IL-1β, IL-6, TNF-α and PGE₂. Chondroitin sulfate (from chicken) improves motor function, protects cartilage tissue, reverses chondrocyte aggregation, and regulates the structure of intestinal flora. Chondroitin sulfate (from chicken) can be used in research related to osteoarthritis .

Cat. No.	Product Name	Target	Research Area

HY-P11650

HE4-1 leech peptide	p38 MAPK JNK	Cardiovascular Disease
HE4-1 leech peptide is a p38 MAPK inhibitor with an additional c-Jun N-terminal kinase (JNK) inhibitory role. HE4-1 leech peptide suppresses macrophage migration, and does not significantly affect macrophage immunological activities including phagocytic ability, lysozyme activity, and expression levels of most inflammatory factors. HE4-1 leech peptide can be used for the research of atherosclerosis .

Cat. No.	Product Name	Chemical Structure

HY-10405S

Pamapimod-d4

Pamapimod-d₄ (Ro4402257-d₄) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC₅₀s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: